We are happy to announce you the cASPerCF has opened the first two sites participating in the Study and can now start the patient’s recruitment.
The first Site Initiation Visit (SIV) was held on February 12th, 2021 at the Ospedale Pediatrico Bambino Gesù (OPBG) in Rome, followed by the second SIV held on March 9th, 2021 at the Azienda Socio Sanitaria Territoriale degli Spedali Civili in Brescia.
cASPerCF study will test an antifungal drug called posaconazole in children and young people aged 8-17 years with Cystic Fibrosis and Aspergillus infection.
cASPerCF is a non-industry proof of viability study performed under the c4c Project. The Sponsor of the Study is Ospedale Pediatrico Bambino Gesù (OPBG), Italy and the Coordinating Centre for the study is the Exeter Clinical Trials Unit located at the University of Exeter, UK.
In this study CVBF is responsible for Sites Assessment, Data Management, Study Monitoring, Trial Master File preparation and maintenance.